Blueprint Medicines Corporation
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
About
CEO
Ms. Kathryn Haviland M.B.A.
Employees
638
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
45 Sidney Street, Cambridge, MA 02139, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 28, 2025 | — | — | — | — |
| Jul 30, 2025 | — | — | — | — |
| Apr 30, 2025 | — | — | — | — |
| Feb 13, 2025 | -0.68 | — | — | — |
| Oct 30, 2024 | -0.97 | -0.89 | 0.08 | -8.25% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 6 | — | 9 |
| Average estimate | — | -0.57 | — | -0.93 |
| Low estimate | — | -0.78 | — | -2.84 |
| High estimate | — | -0.40 | — | 2.92 |
| Last year EPS | — | -1.32 | — | -1.33 |
[stock_revenue_estimate]
Growth estimates
Current qtr
61.810%
Next qtr. (Mar 2025)
57.170%
Current year
84.060%
Next year (Dec 2025)
29.940%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 249.38M | 204.04M | 180.08M | 793.74M | 66.51M |
| Cost of revenue | 8.54M | 17.81M | 17.93M | 425,000 | — |
| Gross profit | 240.84M | 186.22M | 162.15M | 793.31M | 66.51M |
| Operating expense | |||||
| Research & development | 427.72M | 477.42M | 601.03M | 326.86M | 331.45M |
| Selling general and admin | 295.14M | 237.37M | 195.29M | 157.74M | 96.39M |
| Other operating expenses | — | 8.95M | 7.80M | — | — |
| Operating income | -482.02M | -528.57M | -634.18M | 308.71M | -361.33M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | — | — | — | — | — |
| Other income expense | -5.20M | -6.94M | -9.29M | -366,000 | -100,000 |
| Pretax income | -506.02M | -552.28M | -641.08M | 314.94M | -347.69M |
| Tax provision | 968,000 | 5.24M | 3.00M | 1.06M | — |
| Net income | -506.98M | -557.52M | -644.09M | 313.88M | -347.69M |
| Basic EPS | -8.37 | -9.35 | -11.01 | 5.76 | -7.27 |
| Diluted EPS | -8.37 | -9.35 | -11.01 | 5.59 | -7.27 |
| Basic average shares | 60.56M | 59.64M | 58.52M | 54.53M | 47.83M |
| Diluted average shares | 60.56M | 59.64M | 58.52M | 54.53M | 47.83M |
| EBITDA | -470.36M | -516.84M | -627.70M | 315.27M | -356.07M |
| Net income from continuing op. | -506.98M | -557.52M | -644.09M | 313.88M | -347.69M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1.05B | 1.35B | 1.25B | 1.72B | 707.69M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 71.29M | 119.71M | 209.95M | 684.64M | 113.94M |
| Other short term investments | 639.36M | 825.28M | 267.17M | 187.21M | 369.62M |
| Accounts receivable | 42.83M | 23.53M | 25.16M | 7.10M | 663,000 |
| Other receivables | 351,000 | 13.41M | 11.88M | 18.21M | 22.75M |
| Inventory | 21.22M | 29.70M | 21.82M | 8.58M | — |
| Prepaid assets | — | — | 18.06M | 22.02M | 9.82M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 33.35M | 35.02M | 18.06M | 22.02M | 9.82M |
| Non current assets | |||||
| Properties | 95.00M | 97.58M | 103.28M | 78.96M | 81.73M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 7.33M | 6.25M | 5.84M | 5.35M | 5.49M |
| Construction in progress | 9.51M | 1.61M | 213,000 | 151,000 | 956,000 |
| Leases | 42.30M | 41.05M | 36.95M | 36.95M | 36.63M |
| Accumulated depreciation | -38.49M | -31.28M | -25.42M | -19.73M | -13.68M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | 84.32M | 161.27M | 557.53M | 677.87M | 64.41M |
| Other non current assets | 40.89M | 26.78M | 19.81M | 11.09M | 15.39M |
| Total liabilities | 918.64M | 835.23M | 281.49M | 248.31M | 243.34M |
| Current liabilities | |||||
| Accounts payable | 4.71M | 2.73M | 8.33M | 4.37M | 4.79M |
| Accrued expenses | 67.09M | 91.33M | 88.74M | 77.35M | 75.19M |
| Short term debt | 42.21M | 27.43M | 8.09M | 7.94M | 6.82M |
| Deferred revenue | 40.01M | 21.95M | 11.51M | 12.56M | 6.16M |
| Tax payable | — | — | — | — | — |
| Pensions | 43.43M | 30.74M | 29.17M | 27.62M | 13.52M |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 290.29M | 215.02M | 103.32M | 81.67M | 89.13M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 6.21M | 10.30M | 3.34M | 7.24M | 7.81M |
| Shareholders equity | |||||
| Common stock | 61,000 | 60,000 | 59,000 | 58,000 | 49,000 |
| Retained earnings | -2.34B | -1.83B | -1.28B | -631.36M | -945.24M |
| Other shareholders equity | -3.50M | -10.44M | -4.13M | -5.21M | -2.54M |
| Total shareholders equity | 130.61M | 514.68M | 970.74M | 1.47B | 464.36M |
| Additional paid in capital | 2.47B | 2.36B | 2.25B | 2.11B | 1.41B |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Net Income | -506.98M | -557.52M | -644.09M | 313.88M | -347.69M | -236.64M | -148.12M | -72.50M | -52.77M | -40.29M | -20.91M |
| Depreciation | 11.67M | 11.74M | 6.48M | 6.56M | 5.26M | 4.25M | 1.58M | 1.58M | 948,000 | 622,000 | 501,000 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 92.67M | 98.97M | 91.63M | 75.53M | 54.65M | 30.53M | 12.52M | 6.14M | 5.18M | 2.33M | 351,000 |
| Other Non-Cash Items | 24.39M | -715,000 | 269.64M | 6.22M | 4.99M | -6,000 | 32,000 | 73,000 | 109,000 | 85,000 | 26,000 |
| Accounts Receivable | -7.65M | -2.23M | -11.81M | -1.85M | -23.20M | 198,000 | 3.16M | -163,000 | -3.41M | — | — |
| Accounts Payable | 1.88M | -5.82M | 4.22M | -791,000 | 1.45M | -445,000 | 1.53M | 4,000 | 1.39M | -512,000 | 541,000 |
| Other Assets & Liabilities | -39.64M | -38.15M | -26.88M | -16.57M | -2.17M | -3.65M | 2.00M | 32.80M | 15.96M | -140,000 | -94,000 |
| Operating Cash Flow | -423.66M | -493.73M | -310.80M | 382.98M | -306.71M | -205.76M | -127.29M | -32.06M | -32.60M | -37.90M | -19.59M |
| Investing Activities | |||||||||||
| Capital Expenditures | -16.06M | -8.92M | -3.09M | -3.16M | -14.01M | -12.68M | -15.51M | -2.35M | -4.88M | -700,000 | -257,000 |
| Net Intangibles | — | — | -258.15M | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -766.36M | -489.71M | -655.45M | -969.44M | -738.39M | -801.24M | -360.84M | -264.47M | — | — | — |
| Sale of Investments | 1.06B | 349.37M | 690.83M | 538.35M | 735.93M | 652.83M | 304.00M | 48.00M | — | — | — |
| Investing Cash Flow | 274.04M | -149.54M | 32.29M | -434.25M | -16.47M | -161.09M | -75.85M | -218.70M | -6.08M | -700,000 | -257,000 |
| Financing Activities | |||||||||||
| Long-Term Debt Issuance | 97.93M | 137.79M | — | — | — | — | — | — | — | 7.00M | 3.00M |
| Long-Term Debt Payments | — | — | — | — | — | -1.53M | -2.58M | -3.33M | -1.81M | -750,000 | — |
| Other Financing Charges | -44,000 | 415.83M | — | — | -116,000 | -443,000 | -965,000 | -143,000 | -2.05M | -18,000 | -48,000 |
| Financing Cash Flow | 97.89M | 553.61M | — | 582.49M | 327.35M | -1.97M | 543.95M | 132.58M | 153.22M | 81.35M | 17.99M |
| Other Cash Details | |||||||||||
| End Cash Position | 81.52M | 124.90M | 215.12M | 689.80M | 119.60M | 73.43M | 405.07M | 53.34M | 162.71M | 47.24M | 1.99M |
| Income Tax Paid | — | 6.51M | 694,000 | 778,000 | 185,000 | 123,000 | 37,000 | — | — | — | — |
| Interest Paid | 38.47M | 9.81M | — | — | 5,000 | 267,000 | 151,000 | 316,000 | 452,000 | 215,000 | 53,000 |
| Free Cash Flow | -452.91M | -511.20M | -559.89M | 383.88M | -292.03M | -187.69M | -135.38M | -26.87M | -36.56M | -36.10M | -19.28M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Specialized-Health Care Fund | Oct 31, 2024 | 2,090,064 | 237.01M | 3.29% |
| Price (T.Rowe) New Horizons Fund | Sep 30, 2024 | 2,064,248 | 234.09M | 3.25% |
| Vanguard Total Stock Market Index Fund | Sep 30, 2024 | 1,998,643 | 226.65M | 3.15% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,767,009 | 200.38M | 2.78% |
| Vanguard Small-Cap Index Fund | Sep 30, 2024 | 1,585,695 | 179.82M | 2.50% |
| Price (T.Rowe) Health Sciences Fund | Sep 30, 2024 | 1,461,318 | 165.71M | 2.30% |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | Nov 30, 2024 | 1,277,594 | 144.88M | 2.01% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 951,573 | 107.91M | 1.50% |
| Delaware Group Equity Fds V-Small Cap Core Fund | Nov 30, 2024 | 908,168 | 102.99M | 1.43% |
| Vanguard Small-Cap Growth Index Fund | Sep 30, 2024 | 874,422 | 99.16M | 1.38% |
Article
Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Feb 6, 2025
Article
Should You Buy Blueprint Medicines (BPMC) After Golden Cross?
After reaching an important support level, Blueprint Medicines Corporation (BPMC) could be a good stock pick from a technical perspective. BPMC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Feb 6, 2025
Article
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
CAMBRIDGE, Mass. , Feb. 5, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
Feb 5, 2025
